

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/036150 A1

(43) International Publication Date
17 February 2022 (17.02.2022)

(51) International Patent Classification:

C12N 5/074 (2010.01) C12N 5/077 (2010.01)
C12N 5/071 (2010.01) A61K 31/351 (2006.01)

(21) International Application Number:

PCT/US2021/045822

(22) International Filing Date:

12 August 2021 (12.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/065,342	13 August 2020 (13.08.2020)	US
63/136,137	11 January 2021 (11.01.2021)	US
63/151,628	19 February 2021 (19.02.2021)	US
63/175,030	14 April 2021 (14.04.2021)	US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: SANA BIOTECHNOLOGY, INC. [US/US];
188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(72) Inventors: SCHREPFER, Sonja; 1 Tower Place, Suite 500, South San Francisco, CA 94080 (US). HARR, Steve; 188 East Blaine Street, Suite 400, Seattle, WA 98102 (US). MURRY, Charles, E.; 188 East Blaine Street, Suite 400, Seattle, WA 98102 (US).

(74) Agent: MACDOUGALL, Christina, A. et al.; Morgan, Lewis & Bockius LLP, One Market, Spear Street Tower, San Francisco, CA 94105 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: METHODS OF TREATING SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS, AND ASSOCIATED METHODS AND COMPOSITIONS

(57) Abstract: Disclosed herein are hypoimmunogenic cells for administering to a sensitized patient. In some instances, the patient is sensitized from a previous pregnancy or a previous transplant. In some embodiments, the cells exogenously express CD47 proteins and exhibit reduced expression of MHC class I proteins, MHC class II proteins, or both.

WO 2022/036150 A1